Mindray Medical International Limited MR Securities Stock Fraud

- by

Company: Mindray Medical International Limited
Ticker Symbol: MR
Class Period: Jan-11-10 to Aug-9-10
Date Filed: Jul-27-11
Lead Plaintiff Deadline: Sep-25-11
Court: --
Dallas, TX: A federal securities class action lawsuit has been filed against Mindray Medical International Limited ("Mindray" or "MR") during the period of January 11, 2010 and August 9, 2010 (the "Class Period").

It has been alleged that during the Class Period, Mindray and certain of its officers and directors made materially false and misleading statements or failed to disclose material information related to the company's business and operations in violation of the Securities Exchange Act of 1934. Specifically, it is alleged that the defendants misrepresented and/or failed to disclose the following adverse facts: (a) that Mindray was experiencing declining sales domestically due to the lack of Chinese government tenders and a slowdown in non-tender Chinese sales; (b) that Mindray's sales of its diagnostics and ultrasound equipment were not performing according to internal expectations; (c) that Mindray was confronting increased competition in the market for larger hospital systems in China; and (d) that, as a result of the foregoing, defendants lacked a reasonable basis for their positive statements about the Mindray and its prospects.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Mindray Medical International Limited MR Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Mindray Medical International Limited securities class action lawsuit. Please fill in our form on the right to submit your complaint for a free evaluation.

Maybe it's your stockbroker

Add Your Comment on This Issue

Please read our comment guidelines before posting.

Note: Your name will be published with your comment.

Your email will only be used if a response is needed.

Request Legal Help